Introduction

Oncology Reports

1021-335X 1791-2431

D.A. Spandidos

10.3892/or.2021.8009

OR-0-0-8009

Articles

Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells

Pérez

Gisella

1 * López-Moncada

Fernanda

2 * Indo

Sebastián

3 Torres

María José

1 Castellón

Enrique A.

1 Contreras

Héctor R.

1Laboratory of Cellular and Molecular Oncology, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago 8380453, Chile 2Laboratory of Endocrinology and Reproductive Biology, University of Chile Clinical Hospital, Faculty of Medicine, University of Chile, Santiago 8380453, Chile 3Department of Medical Technology, Faculty of Medicine, University of Chile, Santiago 8380453, Chile

Correspondence to: Dr Héctor R. Contreras or Dr Enrique A. Castellón, Laboratory of Cellular and Molecular Oncology, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Avenida Independencia 1027, Santiago 8380453, Chile, E-mail: hcontrer@med.uchile.cl, E-mail: ecastell@med.uchile.cl *

Contributed equally

05 2021

10 03 2021

45 5

10082020 26012021

2021

Prostate cancer (PCa) is the second most diagnosed type of cancer in men worldwide. Advanced PCa is resistant to conventional therapies and high recurrence has been associated with high rates of metastasis. Cancer stem cells (CSCs) have been proposed to be responsible for this, due to their ability of self-renewal and differentiation into other cell types. Zinc finger E-box-binding homeobox 1 (ZEB1), a transcription factor involved in the regulation of epithelial-mesenchymal transition (EMT), has been associated with the activation of several mechanisms that lead to resistance to treatment. As recent evidence has shown that CSCs may originate from non-CSCs during EMT, it was hypothesized that knocking down ZEB1 expression in PCa cell lines could revert some properties associated with CSCs. Using lentiviraltransduction, ZEB1 expression was silenced in the PCa DU145 and LNCaP cell lines. The mRNA and protein expression levels of key canonical CSC markers (Krüppel-like factor 4, SOX2, CD44 and CD133) were determined using reverse transcription-quantitative PCR and western blot analysis, respectively. In addition, the colony forming ability of the ZEB1-knockdown cells was evaluated, and the type of colonies formed (holoclones, paraclones and meroclones) was also characterized. Finally, the ability to form prostatospheres was evaluated in vitro. It was found that in ZEB1-knockdown DU145 cells, the expression levels of CSC phenotype markers (CD44, CD133 and SOX2) were decreased compared with those in the control group. Furthermore, ZEB1-knockdown cells exhibited a lower ability to form prostatospheres and to generate colonies. In conclusion, stable silencing of ZEB1 reversed CSC properties in PCa cell lines. Since ZEB1 is associated with malignancy, therapy resistance and a CSC phenotype in PCa cell lines, targeting ZEB1 may be a key factor to eradicate CSCs and improve the prognosis of patients with advanced PCa.

cancer stem cells epithelial-mesenchymal transition zinc finger E-box-binding homeobox 1 prostate cancer

FondoNacional de Ciencia y Tecnología

1151214

1201704

U-Redes

007/17

The present study was supported by grants from the FondoNacional de Ciencia y Tecnología (grant nos. 1151214 and 1201704) and U-Redes (grant no. 007/17).

Introduction

Prostate cancer (PCa) is the second most common type of cancer in men and the fourth leading cause of cancer-associated death worldwide, according to GLOBOCAN 2018 statistics (1). In addition, mortality is mainly associated with the age of diagnosis, degree of histological differentiation, metastasis and resistance to hormonal therapy, with the latter being one of the greatest challenges in PCa management (2,3). Androgen deprivation therapy (ADT), mainly achieved with gonadotropin-releasing hormone analogs, is the first-line therapy to treat metastatic PCa. Patients with advanced PCa initially respond to ADT, showing decreased tumor size and blood prostate-specific antigen levels (4,5). However, after two or three years, nearly all patients relapse, progressing to castration-resistant PCa (CRPC) (3,6). Increasing evidence has indicated that cancer stem cells (CSCs), a small subpopulation of malignant cells with stem-like properties, may serve an important role in the progression of CRPC (7–11).

Functionally, CSCs are defined by their ability of self-renewal and asymmetric division, giving rise to heterogeneous cell lines (12). Prostate CSCs are able to initiate the development of tumors in the metastatic niche and to differentiate into cancer cells with highly aggressive phenotypes, contributing to the progression of the disease (13,14). From a molecular standpoint, CSCs are characterized by the expression of specific surface markers; in particular, prostate CSCs express CD133 (also known as prominin-1) and CD44, and high levels of the multidrug resistance pump ATP binding cassette subfamily G member 2 and integrin α2β1 (10,15,16).

CSCs contribute to cancer progression due to their resistance to different therapeutic approaches (17–19). Prostate CSCs are not sensitive to ADT, due to not expressing the androgen receptor (AR) (9,10,16). Furthermore, CSCs exhibit abnormal activation of DNA repair pathways, low proliferation rates and high expression levels of multidrug resistance efflux pumps (15–17,19). These intrinsic characteristics of CSCs may account for the failure of radio- and chemotherapy in patients with CRPC (16,20,21).

Due to their importance in PCa progression, CSCs have become a potential target for advanced PCa. However, the origin and molecular mechanisms of CSCs are not fully understood. It has been suggested that CSCs may originate from the malignant transformation of normal prostate stem cells (22); however, several studies have indicated that CSCs may originate from non-CSCs (23–25). Notably, numerous molecular networks have been found to induce reprogramming of non-CSCs into CSCs and have been involved in epithelial-mesenchymal transition (EMT) (14,26,27).

EMT is a trans-differentiation mechanism, in which epithelial cells change their phenotype and acquire mesenchymal features. The main change that occurs during EMT is the loss of E-cadherin expression, resulting in loss of apicobasal polarity and cell-cell contact, and increased migration and invasion (28). In cancer cells, several signaling pathways can initiate and maintain EMT, including the transforming growth factor-β, Wnt/β-catenin and integrin/integrin-linked kinase signaling pathways (28–30). These signaling pathways converge on the activation of EMT transcription factors, which directly inhibit E-cadherin expression (31,32). Among these transcription factors, zinc finger E-box-binding homeobox 1 (ZEB1) has been associated with the activation of several mechanisms leading to resistance to treatment (33–36). It has been previously demonstrated that ZEB1 induces EMT in PCa cell lines, promoting the loss of E-cadherin expression, and increases migration and invasion, resulting in an aggressive phenotype (37–39). Accordingly, ZEB1 is expressed at higher levels in the highly aggressive DU145 cell line compared with in other PCa cell lines, such as PC3, LNCaP and 22Rv1 cells (38). Knocking down ZEB1 expression in the DU145 cell line increases E-cadherin expression and decreases invasion and migration (38). Furthermore, DU145 cells exhibit some characteristics of CSCs, such as chemotherapy resistance, and the stable knockdown of ZEB1 sensitizes these cells to docetaxel, a taxane widely used for the treatment of CRPC (37). Based on the aforementioned studies, the present study hypothesized that knocking down ZEB1 in PCa cells could also revert some features associated with CSCs.

Materials and methods <sec> <title>Cell culture

The PCa DU145 (ATCC^®HTB81™) and LNCaP clone FGC (ATCC^®CRL1740™) cell lines were purchased from the American Type Culture Collection. DU145 cells were originally obtained from a brain metastasis of PCa and are insensitive to androgens, resembling CRPC (40). LNCaP cells were originally obtained from a lymph node metastasis of PCa and are responsive to androgens (41). DU145 cells were maintained in DMEM F12 medium and LNCaP cells were maintained in RPMI-1640 medium (both Gibco; Thermo Fisher Scientific, Inc.). Both culture media were supplemented with 10% fetal bovine serum (Corning Life Sciences), streptomycin-penicillin and amphotericin B (Corning, Inc.). Cell cultures were maintained at 37°C in a humidified atmosphere with 5% CO₂.

Lentiviral transduction

Knockdown of ZEB1 expression in DU145 and LNCaP cells was achieved using transduction with lentiviral vectors containing a short hairpin (sh)RNA against ZEB1 [pLenti-U6-shRNA (hZEB1)-Rsv(RFP-Puro)], or a scrambled shRNA used as a negative control [pLenti-U6-shRNA (Neg-control)-Rsv(RFP-Puro)]. Pre-packaged lentiviral particles were purchased ready to use from GenTarget, Inc., and cells were infected using a standard procedure. Briefly, 10⁶ cells/well were seeded in 6-well plates. After 24 h at 37°C, cells were incubated with lentiviral particles at a multiplicity of infection of 3, with 6 µg/ml polybrene (Sigma-Aldrich; Merck KGaA) in 1 ml culture medium for 24 h at 37°C. Subsequently, cells integrating the vectors were selected using 2 µg/ml puromycin for 24 h at 37°C.

Western blotting

Whole-cell protein was extracted from cells using RIPA buffer with cOmplete™ Mini, EDTA-free protease inhibitor cocktail (Roche Diagnostics), and protein concentration was determined using a Bradford protein assay. A total of 50 µg protein/lane was separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane. Blots were blocked for 1 h at room temperature with 5% BSA (Winkler Ltda) in 0.2% TBS-Tween and incubated overnight at 4°C with primary antibodies diluted in blocking buffer. After washing three times in 0.2% TBS-Tween, bound primary antibodies were detected with HRP-conjugated secondary antibodies incubated for 1.5 h at room temperature, and revealed with an enhanced chemiluminescence detection kit for HRP (EZ-ECL; Biological Industries). Chemiluminescence was detected using the Fusion FX image system (VilberLourmat) and the optical density of the bands was analyzed using the software ImageJ v1.51 (National Institutes of Health).

The antibodies used were as follows: SOX2 (1:1,000; cat. no. ab92494; Abcam), Krüppel-like factor 4 (KLF4; 1:1,000; cat. no. ab215036; Abcam), CD44 (1:5,000; cat. no. ab51037; Abcam), CD133 (1:500; cat. no. Pas-38014; Thermo Fisher Scientific, Inc.), ZEB1 (1:1,000; cat. no. Pa5-28221; Thermo Fisher Scientific, Inc.), E-cadherin (1:1,000; cat. no. 610181; BD Biosciences), β-actin (1:5,000; cat. no. 691002; MP Biomedicals, LLC), anti-mouse HRP (1:10,000; cat. no. 115-035-003; Jackson ImmunoResearch Laboratories, Inc.) and anti-rabbit HRP (1:10,000; cat. no. 111-035-003; Jackson ImmunoResearch Laboratories, Inc.).

RNA extraction and reverse transcription-quantitative (q)PCR

Total RNA was extracted from cells using TRIzol (Ambion; Thermo Fisher Scientific, Inc.). A total of 3,000 ng cDNA was synthesized using the cDNA Affinity Script QPCR kit (Agilent Technologies, Inc.), according to the manufacturer's protocol, and 100 ng cDNA was amplified by qPCR using the Brilliant II SYBR Green qPCR Master Mix kit (Agilent Technologies, Inc.) according to the manufacturer's protocol. For qPCR, the thermocycling conditions were as follows: Initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 sec, annealing at 60°C for 15 sec and extension at 72°C for 15 sec. The housekeeping gene pumilio RNA binding family member 1 was used as a normalizer (42) and the results were analyzed using the 2^−ΔΔCq method (43). The primer sequences used for qPCR are presented in Table I.

Colony formation assay

Cells cultured under adherent conditions were detached using 0.25% trypsin at 37°C for 10 min, seeded at 2×10⁴ cells/plate in 6-well plates and incubated at 37°C in a humidified atmosphere with 5% CO₂. After 15 days, cells were fixed for 10 min at room temperature with cold 100% methanol, stained with crystal violet (0.5% crystal violet in 25% methanol) for 10 min at room temperature, washed and air-dried at room temperature. The resulting colonies were photographed using an Olympus SZ60 stereoscopic light microscope (Olympus Corporation), and the images were analyzed using ImageJ v1.51 (National Institutes of Health). Groups of ≥50 cells were considered as colonies, and the types of colonies formed were classified according to their morphology in holoclones, meroclones and paraclones, as previously described by Barrandon and Green (44).

Prostatosphere formation assay

Cells from cultures maintained under adherent conditions were washed with PBS and detached using acutase (eBioscience; Thermo Fisher Scientific, Inc.) for 7 min at 37°C. The collected cells were centrifuged at 300 × g for 5 min at room temperature, and the pellet was mechanically disaggregated using a micropipette and collected through a 40-µm cell strainer (BD Falcon; Becton, Dickinson and Company). Cells (1×10⁵) were seeded in 6-cm dishes coated with 1% agarose in a culture medium suitable for inducing cell growth under non-adherent conditions, as previously described (15). Prostatospheres were photographed every other day for a total of 7 days using an Olympus SIG60 stereoscopic light microscope (Olympus Corporation; magnification, ×100) and analyzed using the software AxioVision v4.8.1 (Carl Zeiss AG), as described by Acikgoz et al (45). Prostatosphere 3D volume was calculated from 2D images using the following formula: (length × width × width) × (3.1416/6).

Statistical analysis

Data analysis was performed using GraphPad Prism 6.0 software (GraphPad Software, Inc.). Data are expressed as the mean ± standard deviation of at least three independent experiments, and the Mann-Whitney U test was used to analyze differences between groups. P≤0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>Knockdown of ZEB1 in the PCa DU145 cell line

To determine whether ZEB1 could revert some of the CSC features in PCa cells, knockdown of ZEB1 expression in the PCa DU145 cell line was performed using transduction with lentiviral vectors expressing a shRNA targeting ZEB1 (DU145 sh-ZEB1). Scramble shRNA was used as a control (DU145 sh-Scr). The cells transduced with ZEB1 shRNA formed cohesive groups in adherent conditions (Fig. 1A) and sh-ZEB1 significantly decreased ZEB1 mRNA (Fig. 1B) and protein expression (Fig. 1C and D) compared with sh-Scr. ZEB1 is a known transcriptional repressor of E-cadherin. Therefore, to evaluate whether knocking down ZEB1 expression in these cells modified E-cadherin expression, E-cadherin protein expression was determined using western blot analysis. As shown in Fig. 1C and D, ZEB1-knockdown significantly increased E-cadherin expression.

Knockdown of ZEB1 in DU145 cells decreases the expression levels of the CSC markers CD44 and CD133

In the established ZEB1-knockdown cell line, the expression levels of the CSC markers CD44 and CD133 were evaluated. Reverse transcription-qPCR revealed that DU145 cells transduced with sh-ZEB1 exhibited significantly decreased mRNA expression levels of CD44 and CD133 compared with DU145 cells transduced with sh-Scr (Fig. 2A). These results were verified using western blot analysis (Fig. 2B), revealing that ZEB1-knockdown induced a significant decrease of ~75 and 20% of CD44 and CD133 protein expression, respectively (Fig. 2C).

Knockdown of ZEB1 in DU145 cells decreases SOX2 expression

Since ZEB1-knockdown decreased the expression levels of the CSC markers CD44 and CD133, which in turn are controlled by CSC transcription factors, such as KLF4 and SOX2, the present study further investigated whether ZEB1-knockdown affected the expression levels of these transcription factors. ZEB1-knockdown in the DU145 cell line significantly decreased the expression levels of SOX2, at both the mRNA and protein level; however, the expression levels of KLF4 were not significantly changed at the mRNA level, but were significantly decreased at the protein level (Fig. 3).

Effect of ZEB1-knockdown on the colony forming ability of DU145 cells

One of the main characteristics of CSCs is the ability of self-renewal. To determine if ZEB1-knockdown in PCa cells affected this ability, a colony formation assay was performed, in which single cells that self-renew will form colonies of the clones. ZEB1-knockdown significantly decreased the number of colonies formed by DU145 cells (Fig. 4A and B). Furthermore, the types of colonies formed by DU145 cells transduced with sh-ZEB1 were different compared with those in cells transduced with sh-Scr, with respect to size and morphology. The colonies were classified into holoclones, meroclones and paraclones (44): Holoclones are colonies of small and densely compact cells, with regular edges, paraclones consist of larger and elongated cells that grow in a scattered way, with irregular edges, and meroclones have an intermediate morphology, between a paraclone and a holoclone. DU145 cells transduced with either sh-Scr or sh-ZEB1 formed all three types of the colonies (Fig. 4C); however, cells transduced with sh-Scr formed mainly holoclones, whereas cells transduced with sh-ZEB1 formed a high percentage of paraclones (Fig. 4D). In all cases, the mean number of cells per colony was significantly higher in the colonies formed by cells transduced with sh-Scr compared with that in colonies with cells transduced with sh-ZEB1 (Fig. 4E).

Effect of ZEB1-knockdown on the anchorage-independent growth ability of DU145 cells

Prostate CSCs can grow in an anchorage-independent manner forming prostatospheres when cultured in soft agar (46). Prostatospheres formed by cells transduced with sh-Scr and sh-ZEB1 were obtained following 7 days of anchorage-independent growth. There was a higher number of prostatospheres formed by cells transduced with sh-Scr compared with cells transduced with sh-ZEB1 after 1 and 3 days (Fig. 5A and B). Furthermore, the prostatospheres formed by cells transduced with sh-Scr were bigger compared with those formed by cells transduced with sh-ZEB1 after 5 and 7 days (Fig. 5C and D). Therefore, ZEB1-knockdown in DU145 cells affected their ability to generate prostatospheres in anchorage-independent cultures.

Effect of ZEB1-knockdown on the expression levels of CSC markers, clonogenicity and prostatosphere forming ability in LNCaP cells

The DU145 cell line is characterized by a lack of the AR and by their high aggressiveness (47), which are intrinsic characteristics of CRPC. To evaluate if knocking down ZEB1 exerted the same effects in androgen-sensitive cells, ZEB1 expression was knocked down in another PCa cell line, LNCaP. In these cells, the expression levels of E-cadherin, CD44, CD133, SOX2 and KLF4 were investigated, and the results revealed that ZEB1-knockdown significantly increased E-cadherin protein expression and significantly decreased SOX2 protein expression; however, no significant changes were observed in the expression levels of CD44, CD133 and KLF4 (Fig. 6A and B). To assess the ability of self-renewal of the LNCaP ZEB1-knockdown cells, a colony formation assay was performed. ZEB1-knockdown in LNCaP cells did not affect the number or size of the colonies formed (Fig. 6C-E). However, it modified the morphology of the colonies, forming significantly fewer holoclones and more meroclones compared with the control cells (Fig. 6F). Finally, to evaluate the ability of these cells for anchorage-independent growth, a prostatosphere formation assay was performed. As shown in Fig. 6G-I, the LNCaP control cells cultured in soft agar formed bigger prostatospherescompared with the LNCaP cells transduced with sh-ZEB1 after 5 and 7 days, although by day 7 the prostatospheres were smaller compared with day 5 as the LNCaP cells disaggregated.

Discussion

The amount of CSCs within a tumor varies and may be important for the prognosis of the disease (16,48–50). Studies in several types of cancer, such as melanoma, breast, colon and prostate cancer, have described CSCs as tumor-initiating cells, as they can generate a new tumor in distant organs in an appropriate cellular environment and contribute to cancer aggressiveness due to their radio- and chemo-resistance, driving recurrence following conventional therapy (17,18,51).

EMT is accompanied by a reactivation of signaling pathways involved in self-renewal, such as the Wnt and Notch signaling pathway, which facilitate changes in the phenotypic profile of cells, with some of them acquiring a more aggressive and/or mesenchymal phenotype, favoring metastasis and invasiveness (52,53). ZEB1 is a transcription factor that modulates EMT, repressing E-cadherin expression and favoring the expression of mesenchymal markers, in coordination with other transcription factors from the SNAIL and TWIST family (38,54,55).

In the present study, the effect of ZEB1-knockdown on the expression levels of E-cadherin and pluripotency genes commonly expressed in embryonic cells, SOX2 (56,57) and KLF4 (58,59), was investigated. It was found that silencing ZEB1 in DU145 cells induced an increase in E-cadherin and a decrease in SOX2 expression. However, ZEB1 silencing did not regulate the expression levels of KLF4. Stoichiometric SOX2 and KLF4 expression is sufficient for pluripotency in the absence of OCT4 (60). However, knocking down SOX2 by itself results in a decrease of stemness and tumor growth, and induces tumor regression in several types of cancer, such a colorectal, breast and lung cancer (61). Considering that SOX2 has been described as one of the transcription factors that is overexpressed in more aggressive cancer cells (62,63), targeting ZEB1 and the consequent decrease of SOX2 expression may impair CSC self-renewal and maintenance in a variety of tumors, including PCa. However, it is not clear whether this effect may be a result of the EMT process or be EMT-independent. Previous studies have reported that SOX2 increases cell proliferation and survival by inducing EMT (64,65). Forced SOX2 expression increases the expression levels of the EMT transcription factors TWIST, SNAI1 and SNAI2 in pancreatic cancer cell lines (66). In PCa, SOX2-knockdown decreases the expression levels of SNAI1 and SNAI2, and inhibits migration and prostatosphere formation (67). Furthermore, knocking down SNAI1 in pancreatic cancer cells increases E-cadherin expression and downregulates SOX2 expression, as well as decreases tumor size in vivo (68). In the PCa PC3 cells, silencing E-cadherin increases the formation of prostatospheres and the expression levels of CD44 and SNAI1 (69). Notably, knocking down SNAI1 in these cells results in a decrease in prostatosphere formation and clonogenicity (69), which is similar to the observed phenotype of the DU145 cells with ZEB1-knockdown in the present study. This suggested that transcriptional factors involved in EMT may be key for the induction of CSC features. On the other hand, a previous study has reported temporary SOX2 and KLF4 expression, mainly during colonization in the metastatic niche by CSCs, which was absent or low during EMT (70).

Consistent with the results of the present study in DU145 cells, knockdown of ZEB1 in LNCaP cells increased E-cadherin and decreased SOX2 expression. However, in LNCaP cells, no changes were observed in the expression levels of the CSC markers, CD44 and CD133. Prostate CSCs are characterized by a molecular signature that includes positive expression of CD44 and CD133 (15). In the present study, it was found that LNCaP cells expressed very low levels of CD44 and CD133. By contrast, DU145 cells were positive for CD44 and CD133 expression, and their expression levels were downregulated by ZEB1-knockdown. A possible explanation for the different results observed may be due to the intrinsic characteristics of both cell lines. LNCaP cells are androgen-sensitive cells derived from a lymph node metastasis (41), representing an earlier stage of PCa, whereas DU145 are androgen-insensitive cells, derived from a brain metastasis (40); therefore, they are more representative of CRPC. Androgen sensitivity of PCa cells serves a role in CSC phenotype and ZEB1 expression. In androgen-sensitive cells, androgens promote the expression levels of ZEB1 via the binding of the AR to androgen response elements present in the ZEB1 promoter (71). Prostate CSCs do not express AR and other prostate epithelial differentiation markers (9,16). However, it has been demonstrated that ZEB1 expression may be induced in AR-null cells (72). Furthermore, in our previous study, ZEB1 expression in PCa cell lines was characterized, revealing that DU145 cells expressed higher levels of ZEB1 compared with LNCaP cells (38). The aforementioned studies, together with the results of the present study, indicated that DU145 cells may be enriched in cell populations that display CSC properties, such as chemotherapy and anoikis resistance, whereas LNCaP cells did not display these characteristics.

Increasing evidence has revealed that ZEB1 is a key factor for the transition between non-CSCs and CSCs in other types of cancer, such as pancreatic and breast cancer (55,73,74). This effect may be mediated by non-coding RNAs inhibiting the expression levels of stemness genes. Several stemness-repressing microRNAs (miRs) have been described (75). Among them, miR-200 may represent the link between ZEB1 and CSCs. It has been demonstrated that ZEB1 and miR-200 are associated with a double-negative feedback loop: ZEB1 inhibits miR-200 expression, which in turn suppresses the translation of ZEB1 mRNA (76). On the other hand, miR-200 also represses the expression levels of SOX2 and KLF4 (75). Therefore, one of the limitations of the present study was the lack of analyzing miR-200 expression following ZEB1-knockdown. It would be interesting to determine whether the downregulation of SOX2 by ZEB1-knockdown would result in the loss of direct interaction between ZEB1 and the SOX2 promoter or through the lack of ZEB1 inhibition on miR-200.

Knocking down ZEB1 in the present study decreased the expression levels of SOX2, as well as the number of colonies formed in vitro and the proportion of holoclones, and increased the number of paraclones. Cells that form holoclones and express CSC markers, such as CD44 and CD133, have the ability of self-renewal, generate cultures in non-adherent conditions and have highly tumorigenic abilities when injected into immunodeficient mice (77,78). On the other hand, paraclones can proliferate, but not self-renew (77). The results in the present study are consistent with the study by Knaack et al (79), which found higher expression levels of ZEB1 in holoclones in pancreatic cancer cells compared with those in paraclones. Moreover, holoclones of pancreatic cancer cells had increased expression levels of TNFα and other pro-inflammatory genes acting as EMT inducers compared with paraclones, which is consistent with the higher expression levels of ZEB1 (79).

The present study also revealed that there was a decrease in the expression levels of CD44 and CD133 in DU145 cells following ZEB1-knockdown. Overexpression of CD44 and SOX2 in PCa cells results in the upregulation of the SNAI1 and SNAI2 transcription factors leading to EMT (67). Overexpression of CD133 in PCa cells increases the expression levels of other CSC markers, decreases E-cadherin expression and enhances migration and bone metastasis formation (80). Furthermore, the presence of CD44 and CD133 have been identified as important factors in the formation of prostatic spheroids, which is directly associated with the ability of self-renewal and anoikis resistance in PCa cells (81). In the present study, knocking down ZEB1 decreased the number of colonies formed in adherent conditions, as well as the number and size of the prostatospheres generated, which is consistent with the observed downregulation of CD44, CD133 and SOX2 expression. Pluripotency genes are important factors in chemoresistance and apoptosis evasion. Overexpression of SOX2 and OCT4 in gastric cancer cells increases their resistance to oxaliplatin and fluorouracil (82). In PCa, CD133⁺ cells, sorted from human 22Rv1 PCa cells, are highly resistant to γ-radiation and docetaxel (83). In T-cell acute lymphoblastic leukemia, CD44 enhances the activity of ATP-binding cassette multidrug efflux transporters, inducing resistance to doxorubicin (84). In agreement with this, our previous study revealed that knocking down ZEB1 in DU145 cells decreases the expression levels of multidrug resistance-associated protein 1 and ATP-binding cassette subfamily C member 4, and enhances their sensitivity to docetaxel (37). This suggested that ZEB1, SOX2, CD44 and CD133 may participate together to promote chemoresistance. Overall, the results of the present study indicated that targeting ZEB1 in PCa decreased the expression levels of CSC markers and affected their function; thus, this may directly impact tumor resistance and recurrence (Fig. 7).

In conclusion, knocking down ZEB1 in aggressive PCa cells decreased the expression levels of the CSC markers CD44 and CD133, and of the transcription factor SOX2. Additionally, compared with the control cells, cells with ZEB1-knockdown exhibited a lower capacity for anchorage-independent growth and self-renewal, important characteristics for metastasis and recurrence. As a future therapy, targeting ZEB1 may reprogram CSCs into non-CSCs, decreasing their number within a tumor, and therefore improving the response to therapy and prognosis of patients with advanced PCa.

Acknowledgements

The authors would like to thank Ms. Graciela Caroca and Ms. Catherine Gatica from the Laboratory of Cellular and Molecular Oncology, Department of Basic and Clinical Oncology, University of Chile (Santiago, Chile), for their technical assistance.

Funding

The present study was supported by grants from the FondoNacional de Ciencia y Tecnología (grant nos. 1151214 and 1201704) and U-Redes (grant no. 007/17).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

GP and FLM designed and performed the experiments, conducted the statistical analysis and wrote the manuscript. SI participated in the design, experimental work and data analysis of LNCaP cells. MJT analyzed the data. EAC and HRC conceived the study, participated in its design and coordination, wrote the manuscript and are responsible for confirming the authenticity of the data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Bray

Ferlay

Soerjomataram

Siegel

Torre

Jemal

Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

CA Cancer J Clin683944242018

10.3322/caac.21492

30207593

Fakhrejahani

Madan

Dahut

Management options for biochemically recurrent prostate cancer

Curr Treat Options Oncol18262017

10.1007/s11864-017-0462-4

28434181

Wang

Ruan

Liu

Yang

Zhang

Chen

Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer

Onco Targets Ther11316731782018

10.2147/OTT.S159777

29881290

Mottet

Bellmunt

Bolla

Briers

Cumberbatch

De Santis

Fossati

Gross

Henry

Joniau

EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent

Eur Urol716186292017

10.1016/j.eururo.2016.08.003

27568654

Cornford

Bellmunt

Bolla

Briers

De Santis

Gross

Henry

Joniau

Lam

Mason

EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer

Eur Urol716306422017

10.1016/j.eururo.2016.08.002

27591931

Chandrasekar

Yang

Gao

Evans

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

Transl Androl Urol43653802015

26814148

Yun

Hsieh

The evolving landscape of prostate cancer stem cell: Therapeutic implications and future challenges

Asian J Urol32032102016

10.1016/j.ajur.2016.09.006

29264188

Chen

Liu

Rycaj

Zhang

Liu

Jeter

Calhoun-Davis

Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer

Clin Cancer Res22450545162016

10.1158/1078-0432.CCR-15-2956

27060154

Deng

Tang

Androgen receptor and prostate cancer stem cells: Biological mechanisms and clinical implications

Endocr Relat Cancer22T209T2202015

10.1530/ERC-15-0217

26285606

Di Zazzo

Galasso

Giovannelli

Di Donato

Di Santi

Cernera

Rossi

Abbondanza

Moncharmont

Sinisi

Prostate cancer stem cells: The role of androgen and estrogen receptors

Oncotarget71932082015

10.18632/oncotarget.6220

Ojo

Lin

Wong

Tang

Prostate cancer stem-like cells contribute to the development of castration-resistant prostate cancer

Cancers (Basel)7229023082015

10.3390/cancers7040890

26593949

Peitzsch

Tyutyunnykova

Pantel

Dubrovska

Cancer stem cells: The root of tumor recurrence and metastases

Semin Cancer Biol4410242017

10.1016/j.semcancer.2017.02.011

28257956

Tsao

Beretov

Bai

Bucci

Graham

Cancer stem cells in prostate cancer radioresistance

Cancer Lett465941042019

10.1016/j.canlet.2019.08.020

31493443

Contreras

López-Moncada

Castellón

Cancer stem cell and mesenchymal cell cooperative actions in metastasis progression and hormone resistance in prostate cancer: Potential role of androgen and gonadotropin-releasing hormone receptors

Int J Oncol56107510822020

32319606

Castellón

Valenzuela

Lillo

Castillo

Contreras

Gallegos

Mercado

Huidobro

Molecular signature of cancer stem cells isolated from prostate carcinoma and expression of stem markers in different Gleason grades and metastasis

Biol Res452943052012

10.4067/S0716-97602012000300011

Castillo

Valenzuela

Huidobro

Contreras

Castellon

Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer

Int J Oncol459859942014

10.3892/ijo.2014.2529

24990514

Carnero

Garcia-Mayea

Mir

Lorente

Rubio

LLeonart

The cancer stem-cell signaling network and resistance to therapy

Cancer Treat Rev4925362016

10.1016/j.ctrv.2016.07.001

27434881

Najafi

Mortezaee

Majidpoor

Cancer stem cell (CSC) resistance drivers

Life Sci2341167812019

10.1016/j.lfs.2019.116781

31430455

Steinbichler

Dudás

Skvortsov

Ganswindt

Riechelmann

Skvortsova

Therapy resistance mediated by cancer stem cells

Semin Cancer Biol531561672018

10.1016/j.semcancer.2018.11.006

30471331

Mitra

Mishra

EMT, CTCs and CSCs in tumor relapse and drug-resistance

Oncotarget610699107102015

10.18632/oncotarget.4037

Leão

Domingos

Figueiredo

Hamilton

Tabori

Castelo-Branco

Cancer stem cells in prostate cancer: Implications for targeted therapy

Urol Int991251362017

10.1159/000455160

28142149

Packer

Maitland

The molecular and cellular origin of human prostate cancer

Biochim Biophys Acta1863123812602016

10.1016/j.bbamcr.2016.02.016

26921821

Sun

Wang

Leong

Yue

Jhunjhunwala

Chen

Seo

Modrusan

Gao

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen-deprivation therapy

Cancer Res72527362012

10.1158/0008-5472.CAN-11-3004

22108827

Kuşoğlu

Biray Avcı

Cancer stem cells: A brief review of the current status

Gene68180852019

10.1016/j.gene.2018.09.052

30268439

Adamowicz

Pakravan

Bakhshinejad

Drewa

Babashah

Prostate cancer stem cells: From theory to practice

Scand J Urol51951062017

10.1080/21681805.2017.1283360

28635565

Lan

Luo

Cui

Shi

Deng

Huo

Chen

Zhang

Deng

Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells

Int J Oncol431131202013

10.3892/ijo.2013.1913

23604232

Eun

Ham

Kim

Cancer stem cell heterogeneity: Origin and new perspectives on CSC targeting

BMB Rep501171252017

10.5483/BMBRep.2017.50.3.222

27998397

Nieto

Huang

RYYJ

Jackson

RAA

Thiery

JPP

EMT: 2016

Cell16621452016

10.1016/j.cell.2016.06.028

27368099

Gonzalez

Medici

Signaling mechanisms of the epithelial-mesenchymal transition

Sci Signal7re82014

10.1126/scisignal.2005189

25249658

Zhang

Tian

Xing

Signal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their Crosstalks

J Clin Med5412016

10.3390/jcm5040041

Sánchez-Tilló

Liu

De Barrios

Siles

Fanlo

Cuatrecasas

Darling

Dean

Castells

Postigo

EMT-activating transcription factors in cancer: Beyond EMT and tumor invasiveness

Cell Mol Life Sci69342934562012

10.1007/s00018-012-1122-2

22945800

Goossens

Vandamme

Van Vlierberghe

Berx

EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET

Biochim Biophys Acta Rev Cancer18685845912017

10.1016/j.bbcan.2017.06.006

28669750

Zhang

Sun

ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance

Cell Cycle144814872015

10.1080/15384101.2015.1006048

25607528

Lazarova

Bordonaro

ZEB1 mediates drug resistance and EMT in p300-deficient CRC

J Cancer8145314592017

10.7150/jca.18762

28638460

Zhang

Wei

Wang

Debeb

Yuan

Zhang

Yuan

Wang

Chen

Sun

ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1

Nat Cell Biol168648752014

10.1038/ncb3013

25086746

Guo

Deng

Yin

Han

Cai

Shen

Zeng

ZEB1 promotes oxaliplatin resistance through the induction of epithelial-mesenchymal transition in colon cancer cells

J Cancer8355535662017

10.7150/jca.20952

29151941

Orellana-serradell

Herrera

Castellón

Contreras

The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines

Asian J Androl214604672019

10.4103/aja.aja_1_19

30880686

Orellana-Serradell

Herrera

Castellón

Contreras

The transcription factor ZEB1 promotes an aggressive phenotype in prostate cancer cell lines

Asian J Androl202942992018

10.4103/aja.aja_61_17

29271397

Farfán

Ocarez

Castellón

Mejía

de Herreros

Contreras

The transcriptional factor ZEB1 represses Syndecan 1 expression in prostate cancer

Sci Rep8114672018

10.1038/s41598-018-29829-1

30065348

Stone

Mickey

Wunderli

Mickey

Paulson

Isolation of a human prostate carcinoma cell line (DU 145)

Int J Cancer212742811978

10.1002/ijc.2910210305

631930

Horoszewicz

Leong

Kawinski

Karr

Rosenthal

Chu

Mirand

Murphy

LNCaP model of human prostatic carcinoma

Cancer Res43180918181983

6831420

Krasnov

Kudryavtseva

Snezhkina

Lakunina

Beniaminov

Melnikova

Dmitriev

Pan-cancer analysis of TCGA data revealed promising reference genes for qPCR normalization

Front Genet10972019

10.3389/fgene.2019.00097

30881377

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method

Methods254024082001

10.1006/meth.2001.1262

11846609

Barrandon

Green

Three clonal types of keratinocyte with different capacities for multiplication

Proc Natl Acad Sci USA84230223061987

10.1073/pnas.84.8.2302

2436229

Acikgoz

Guven

Duzagac

Uslu

Kara

Soner

Oktem

Enhanced G2/M arrest, caspase related apoptosis and reduced E-cadherin dependent intercellular adhesion by trabectedin in prostate cancer stem cells

PLoS One10e01410902015

10.1371/journal.pone.0141090

26485709

Wang

Anchorage-independent growth of prostate cancer stem cells

Methods Mol Biol5681511602009

10.1007/978-1-59745-280-9_9

19582425

Sobel

Sadar

Cell lines used in prostate cancer research: A compendium of old and new lines-Part 1

J Urol1733423592005

10.1097/01.ju.0000141580.30910.57

15643172

Pestellc

Lisantic

Pestell

Cancer Stem Cells

Int J Biochem Cell Biol44214421512012

10.1016/j.biocel.2012.08.022

22981632

Johnston

Maini

Jonathan Chapman

Edwards

Bodmer

On the proportion of cancer stem cells in a tumour

J Theor Biol2667087112010

10.1016/j.jtbi.2010.07.031

20678505

Collins

Berry

Hyde

Stower

Maitland

Prospective identification of tumorigenic prostate cancer stem cells

Cancer Res6510946109512005

10.1158/0008-5472.CAN-05-2018

16322242

Ajani

Song

Hochster

Steinberg

Cancer stem cells: The promise and the potential

Semin Oncol42(Suppl 1)S3S172015

10.1053/j.seminoncol.2015.01.001

25839664

Jolly

Celià-Terrassa

Dynamics of phenotypic heterogeneity during EMT and stemness in cancer progression

J Clin Med815422019

10.3390/jcm8101542

Lamouille

Derynck

Molecular mechanisms of epithelial-mesenchymal transition

Nat Rev Mol Cell Biol151781962014

10.1038/nrm3758

24556840

Hanrahan

O'Neill

Prencipe

Bugler

Murphy

Fabre

Puhr

Culig

Murphy

Watson

The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer

Mol Oncol112512652017

10.1002/1878-0261.12030

28133913

Krebs

Mitschke

Lasierra Losada

Schmalhofer

Boerries

Busch

Boettcher

Mougiakakos

Reichardt

Bronsert

The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer

Nat Cell Biol195185292017

10.1038/ncb3513

28414315

Zhang

Cui

Sox2, a key factor in the regulation of pluripotency and neural differentiation

World J Stem Cells63053112014

10.4252/wjsc.v6.i3.305

25126380

Adachi

Suemori

Yasuda

Nakatsuji

Kawase

Role of SOX2 in maintaining pluripotency of human embryonic stem cells

Genes Cells154554702010

20384793

Ghaleb

Yang

Krüppel-like factor 4 (KLF4): What we currently know

Gene611271372017

10.1016/j.gene.2017.02.025

28237823

Zhang

Andrianakos

Yang

Liu

Kruppel-like factor 4 (Klf4) prevents embryonic stem (ES) cell differentiation by regulating Nanog gene expression

J Biol Chem285918091892010

10.1074/jbc.M109.077958

20071344

Liu

Zheng

Chen

Zhang

Zhou

Ding

Sox2 and Klf4 as the functional core in pluripotency induction without exogenous Oct4

Cell Rep2919862000,e82019

10.1016/j.celrep.2019.10.026

31722212

Mamun

Mannoor

Cao

Qadri

Song

SOX2 in cancer stemness: Tumor malignancy and therapeutic potentials

J Mol Cell Biol1285982020

10.1093/jmcb/mjy080

30517668

Russo

Esposito

Tupone

Manzoli

Airoldi

Pompa

Cindolo

Schips

Sorrentino

Di Carlo

SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis

Oncotarget712372123852016

10.18632/oncotarget.6029

26540632

Zhang

Benelli

Karthaus

Hoover

Chen

Wongvipat

Gao

Cao

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer

Science35584882017

10.1126/science.aah4307

28059768

Liu

Qiao

Zhao

Lam

Tao

Sox2 promotes tumor aggressiveness and epithelial-mesenchymal transition in tongue squamous cell carcinoma

Int J Mol Med42141814262018

29956740

Gao

Teng

Huang

Peng

Wang

SOX2 promotes the epithelial to mesenchymal transition of esophageal squamous cells by modulating slug expression through the activation of STAT3/HIF-α signaling

Int J Mol Sci1621643216572015

10.3390/ijms160921643

26370982

Herreros-Villanueva

Zhang

Koenig

Abel

Smyrk

Bamlet

de Narvajas

Gomez

Simeone

Bujanda

SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells

Oncogenesis2e612013

10.1038/oncsis.2013.23

23917223

Srinivasan

Senbanjo

Majumdar

Franklin

Chellaiah

Androgen receptor expression reduces stemness characteristics of prostate cancer cells (PC3) by repression of CD44 and SOX2

J Cell Biochem120241324282019

10.1002/jcb.27573

Zhou

Liu

Mou

Wang

Snail contributes to the maintenance of stem cell-like phenotype cells in human pancreatic cancer

PLoS One9e874092014

10.1371/journal.pone.0087409

24489910

Deep

Jain

Ramteke

Ting

Vijendra

Gangar

Agarwal

SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin

Mol Cancer13372014

10.1186/1476-4598-13-37

24565133

Celià-terrassa

Meca-cortés

Mateo

Martínez de Paz

Rubio

Arnal-Estapé

Ell

Bermudo

Díaz

Guerra-Rebollo

Epithelial-mesenchymal transition can suppress major attributes of human epithelial

J Clin Invest122184918682012

10.1172/JCI59218

22505459

Anose

Sanders

Androgen receptor regulates transcription of the ZEB1 transcription factor

Int J Endocrinol20119039182011

10.1155/2011/903918

22190929

Mooney

Parsana

Hernandez

Liu

Verdone

Torga

Harberg

Pienta

The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor

J Cell Biochem116115232015

10.1002/jcb.24948

25160502

Chaffer

Marjanovic

Lee

Bell

Kleer

Reinhardt

D'Alessio

Young

Weinberg

Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity

Cell15461742013

10.1016/j.cell.2013.06.005

23827675

Zhou

Jiang

Zhang

Wang

Zhang

Sun

Xiang

Yang

ZEB1 confers stem cell-like properties in breast cancer by targeting neurogenin-3

Oncotarget854388544012017

10.18632/oncotarget.17077

28903350

Pestell

MicroRNAs and Cancer Stem Cells

MicroRNAs in Cancer Translational ResearchWilliam

C.S.C

Springer

3733982011

10.1007/978-94-007-0298-1_16

Brabletz

Bajdak

Meidhof

Burk

Niedermann

Firat

Wellner

Dimmler

Faller

Schubert

Brabletz

The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells

EMBO J307707822011

10.1038/emboj.2010.349

21224848

Tan

Sui

Deng

Ding

Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells

PLoS One6e233832011

10.1371/journal.pone.0023383

21826251

Zhang

Jiao

Zhu

Dang

Wang

Hsieh

Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties

J Cancer Res Clin Oncol1386756862012

10.1007/s00432-011-1146-2

22237455

Knaack

Lenk

Philipp

Miarka

Rahn

Viol

Hauser

Egberts

Gundlach

Will

Liver metastasis of pancreatic cancer: The hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells

Oncotarget931771317862018

10.18632/oncotarget.25884

30167093

Sohn

Kim

Park

Moon

Sun

Jeong

Kim

Lim

Effect of CD133 overexpression on bone metastasis in prostate cancer cell line LNCaP

Oncol Lett18118911982019

31423179

Bisson

Prowse

WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics

Cell Res196836972009

10.1038/cr.2009.43

19365403

Chen

Zhu

Zeng

Gao

Wang

Zhang

Huang

Effect of overexpression of oct4 and sox2 genes on the biological and oncological characteristics of gastric cancer cells

Onco Targets Ther12466746822019

10.2147/OTT.S209734

31417271

Kanwal

Shukla

Walker

Gupta

Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics

Cancer Lett43025332018

10.1016/j.canlet.2018.05.014

29775627

Hoofd

Wang

Lam

Jenkins

Wood

Giambra

Weng

CD44 promotes chemoresistance in T-ALL by increased drug efflux

Exp Hematol44166171.e172016

10.1016/j.exphem.2015.12.001

26708679

Figure 1.

ZEB1-knockdown in the prostate cancer DU145 cell line. (A) Representative microphotographs of DU145 cells transduced with a lentiviral vector carrying Sh-ZEB1 or Sh-Scr. Scale bar, 20 µm. (B) Relative ZEB1 mRNA expression measured via reverse transcription-quantitative PCR. (C) Representative western blots for ZEB1 and E-cadherin protein expression. (D) Quantification of the optical density from the western blots for ZEB1 and E-cadherin protein expression. Data are expressed as the mean ± SD (n=3). *P≤0.05 and ***P≤0.001 (Mann-Whitney U test). ZEB1, ZEB1, zinc finger E-box-binding homeobox 1; Sh-ZEB1, short hairpin RNA against ZEB1; Sh-Scr, scrambled short hairpin RNA.

Figure 2.

ZEB1-knockdown decreases the expression levels of CSC markers in the prostate cancer DU145 cell line. (A) Relative mRNA expression levels of the CSC markers CD44 and CD133 measured via reverse transcription-quantitative PCR in DU145 cells transduced with a lentiviral vector carrying Sh-ZEB1 or Sh-Scr. (B) Representative western blots for CD44 and CD133 protein expression, and (C) their quantification. Data are expressed as the mean ± SD (n=3). **P≤0.01 and ***P≤0.001 (Mann-Whitney U test). ZEB1, ZEB1, zinc finger E-box-binding homeobox 1; Sh-ZEB1, short hairpin RNA against ZEB1; Sh-Scr, scrambled short hairpin RNA; CSC, cancer stem cell.

Figure 3.

ZEB1-knockdown decreases the expression levels of the CSC transcription factor SOX2 in the prostate cancer DU145 cell line. (A) Relative mRNA expression levels of the CSC transcription factors SOX2 and KLF4 measured via reverse transcription-quantitative PCR in DU145 cells transduced with a lentiviral vector carrying Sh-ZEB1 or Sh-Scr. (B) Representative western blots for SOX2 and KLF4 protein expression, and (C) their quantification. Data are expressed as the mean ± SD (n=3). *P≤0.05, **P≤0.01 and ***P≤0.001 (Mann-Whitney U test). ns, not significant; ZEB1, ZEB1, zinc finger E-box-binding homeobox 1; Sh-ZEB1, short hairpin RNA against ZEB1; Sh-Scr, scrambled short hairpin RNA; CSC, cancer stem cell; KLF4, Krüppel-like factor 4.

Figure 4.

ZEB1-knockdown decreases the clonogenic capacity of the prostate cancer DU145 cell line. (A) Representative image of the colony formation assay using DU145 cells transduced with a lentiviral vector carrying Sh-ZEB1 or Sh-Scr. Scale bar, 5 mm. (B) Number of colonies formed after 2 weeks of growth under limiting dilution conditions. (C) Representative images of the type of colonies formed in each condition. Scale bar, 50 µm. (D) Quantification of the different types of colonies formed. (E) Quantification of the cell number of each type of colony. Data are expressed as the mean ± SD (n=3). *P≤0.05, **P≤0.01 and ***P≤0.001 (Mann-Whitney U test). ns, not significant; ZEB1, ZEB1, zinc finger E-box-binding homeobox 1; Sh-ZEB1, short hairpin RNA against ZEB1; Sh-Scr, scrambled short hairpin RNA.

Figure 5.

ZEB1-knockdown decreases the prostatosphere formation capacity of the prostate cancer DU145 cell line. (A) Representative images of the prostatosphere formation assay using DU145 cells transduced with a lentiviral vector carrying Sh-ZEB1 or Sh-Scr. Scale bar, 100 µm. (B) Number of prostatospheres formed after 1 and 3 days of growth under non-adherent conditions. (C) Representative images of the prostatospheres formed in each condition at days 1, 5 and 7 after seeding. Scale bar, 20 µm. (D) Quantification of the size of the prostatospheres formed by each cell line at days 1, 5 and 7 after seeding. Data are expressed as the mean ± SD (n=4). *P≤0.05 and ***P≤0.001 (Mann-Whitney U test). ns, not significant; ZEB1, ZEB1, zinc finger E-box-binding homeobox 1; Sh-ZEB1, short hairpin RNA against ZEB1; Sh-Scr, scrambled short hairpin RNA.

Figure 6.

Effect of ZEB1-knockdown in the prostate cancer LNCaP cell line. (A) Representative western blots for ZEB1, E-cadherin, CD44, CD133, SOX2 and KLF4 protein expression in LNCaP cells transduced with a lentiviral vector carrying Sh-ZEB1 or Sh-Scr. (B) Quantification of optical density of western blots. (C) Representative image of colony formation assay using LNCaP Sh-ZEB1 and Sh-Scr cells. Scale bar, 5 mm. (D) Number of colonies formed after 2 weeks of growth under limiting dilution conditions. (E) Size of the colonies formed by each cell condition. (F) Quantification of the different types of colonies formed. (G) Representative images of the prostatospheres formed in each condition at days 5 and 7 after seeding. Scale bar, 20 µm. (H) Number of prostatospheresformed after 5 and 7 days of growth under non-adherent conditions. (I) Quantification of the size of the prostatospheres formed by each cell line at 5 and 7 days after seeding. Data are expressed as the mean ± SD (n=3). *P≤0.05, **P≤0.01 and ***P≤0.001 (Mann-Whitney U test). ns, not significant; ZEB1, ZEB1, zinc finger E-box-binding homeobox 1; Sh-ZEB1, short hairpin RNA against ZEB1; Sh-Scr, scrambled short hairpin RNA; KLF4, Krüppel-like factor 4; A.U., arbitrary units.

Figure 7.

Representation of the effect of ZEB1 expression on EMT and CSC markers in prostate cancer cells. (A) ZEB1 transcription factor inhibits E-cadherin expression, inducing EMT. ZEB1-knockdown downregulates the stemness transcription factor SOX2 and decreases the expression levels of the prostate CSC markers CD44 and CD133, indicating that ZEB1 may be promoting the expression of these proteins directly (arrows) or indirectly (dashed arrows). A possible mediator may be miR-200, as previous studies (75,76) have shown that it is directly repressed by ZEB1, and in turn, miR-200 directly represses SOX2. (B) Upregulation of SOX2, CD44 and CD133 by ZEB1 may lead to a CSC phenotype. Targeting ZEB1 with small interfering RNAs may reverse this process, decreasing anoikis resistance, self-renewal capacity and chemoresistance of androgen-independent prostate cancer cells. EMT, epithelial-mesenchymal transition; CSC, cancer stem cell; miR, microRNA; ZEB1, zinc finger E-box-binding homeobox 1.

Table I.

Primer sequences used for quantitative PCR.

Gene	Forward primer	Reverse primer
ZEB1	5′-TTCACAGTGGAGAGAAGCCA-3′	5′-GCCTGGTGATGCTGAAAGAG-3′
CD44	5′-CACGTGGAATACACCTGCCA-3′	5′-GACAAGTTTTGGTGGCAGGT-3′
CD133	5′-TCAATTTTGGATTCATATTT-3′	5′-ACTCCCATAAAGCTGGACCC-3′
SOX2	5′-GTCTAGCCTCGTCGATGAAC-3′	5′-AACCCCAAGATGCACAACTC-3′
KLF4	5′-CCCCGTGTGTTTACGGTAGT-3′	5′-AGAGTTCCCATCTCAAGGCA-3′
PUM1	5′-CGTACGTGAGGCGTAAGTAA-3′	5′-CGGTCGTCCTGAGGATAAAA-3′

ZEB1, zinc finger E-box-binding homeobox 1; KLF4, Krüppel-like factor 4; PUM1, pumilio RNA binding family member 1.